Remissions after long-term use of romiplostim for immune thrombocytopenia
View/ Open
File version
Version of Record (VoR)
Author(s)
Marshall, AL
Scarpone, R
De Greef, M
Bird, R
Kuter, DJ
Griffith University Author(s)
Year published
2016
Metadata
Show full item recordAbstract
mmune thrombocytopenia (ITP) is an acquired autoimmune condition whereby autoantibodies against platelets lead to increased platelet clearance, suppression of megakaryocytopoiesis, and subsequent thrombocytopenia.1,2 ITP is associated with increased bleeding risk, and the primary goal of therapy is to prevent clinically significant bleeding. Steroids, and in some cases intravenous immunoglobulin, are recommended first-line therapies.3 However, many patients relapse and alternative therapies including splenectomy, rituximab, and thrombopoietin (TPO) receptor agonists are available for second-line treatment.mmune thrombocytopenia (ITP) is an acquired autoimmune condition whereby autoantibodies against platelets lead to increased platelet clearance, suppression of megakaryocytopoiesis, and subsequent thrombocytopenia.1,2 ITP is associated with increased bleeding risk, and the primary goal of therapy is to prevent clinically significant bleeding. Steroids, and in some cases intravenous immunoglobulin, are recommended first-line therapies.3 However, many patients relapse and alternative therapies including splenectomy, rituximab, and thrombopoietin (TPO) receptor agonists are available for second-line treatment.
View less >
View less >
Journal Title
Haematologica
Volume
101
Issue
12
Copyright Statement
Copyright 2016 Ferrata Storti Foundation. The attached file is reproduced here in accordance with the copyright policy of the publisher. Please refer to the journal's website for access to the definitive, published version.
Subject
Cardiovascular medicine and haematology
immune thrombocytopenic purpura
platelets
romiplostim
thrombopoietin